UDC or Universal Display is an OLED material supplier to display companies. And Iamgarce is part of the herd mentality exhibited here that may be charachterized as a pump or cheerleader type vs objective Research intense investor. I believe EMAN's executive team is smart with their backgrounds in OLED process. What is lacking at the company are: both insightful marketing and financial folks to partner and create shareholder value. Heck, E-Sight product is symbolic of technology leadership in space, as is military products. And product could bring attention to company as well as inroad sales.
Low valuation- After renovations and new openings fundies same store sales will return to historical range.
Low-risk investment here if these guys cross process milestones. The value to a suitor would be an enormous event that could be leveraged (in hands of marketeers) these guys do direct patterning at nit objectives. $4.25 is in sight in my OP.
VR/AV will light up the sky if we surrender our lab coats for profit seeking opps. All food chains are in the game now- Qualcomm reports that its Vuforia platform takes advantage of Snapdragon processors to reduce the "motion-to-photon" latency. This helps deliver a believable, "authentic" augmented reality experience. However, the company indicates that the SDK can be used with other processors, such as the OMAP line from Texas Instruments.
In Sprouts and recommended E-sight to him. Needless, to say he was gracious and excited. Ground funding and publicity is what this device needs. And anybody who has an ounce of intelligenza will know that blindness and eye problems is as much as a medical condition as its is a demographics play=TAM.
Exact Sciences has determined an efficient procedure to identify disease through another type of bodily waste, a stool sample. Similar to how Trovagene uses the function of the kidney to pass cf-NA into urine, Exact Sciences utilizes cells being shed from the colon wall into the stool stream, including cells with altered DNA from polyps that can be the onset of colon cancer. In the test, branded Cologuard, samples are collected and sent to the lab where analysis searches to identify and isolate specific DNA biomarkers associated with cancerous and pre-cancerous conditions. If abnormalities are identified, then a patient will likely be referred by his physician for a colonoscopy to further assess for the presence of cancer.
Its part of the game- Trend will continue if volume and or news show up. Else, momentum (Kramer like circus) will move to the next town.. Stock is deeply discounted relative to OLED space and tech leadership. There's enough of a resonant vibe in VR/AR sector to overcome lack of conveyance of theme for interest in stock or sponsorship.